CO4910113A1 - Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion - Google Patents

Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion

Info

Publication number
CO4910113A1
CO4910113A1 CO97067661A CO97067661A CO4910113A1 CO 4910113 A1 CO4910113 A1 CO 4910113A1 CO 97067661 A CO97067661 A CO 97067661A CO 97067661 A CO97067661 A CO 97067661A CO 4910113 A1 CO4910113 A1 CO 4910113A1
Authority
CO
Colombia
Prior art keywords
preparation
dalphopristine
quinu
pristine
pharmaceutical compositions
Prior art date
Application number
CO97067661A
Other languages
English (en)
Inventor
Jean-Paul Bounine
Guillaume Conrath
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of CO4910113A1 publication Critical patent/CO4910113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Composición farmacéutica estabilizada, a base de laasociación quinupristina/dalfopristina, caracterizada porque comprende una cantidad al menos estequiométrica de ácido metanosulfónico o de ácido clorhídrico y porque su pH está comprendiendo en el intervalo [3,5: 5]. Procedimiento para la preparación de una composición farmacéutica según la reivindicación 1, caracterizado porque se disuelven simultáneamente o sucesivamente la quinupristina, la dalfopristina, el ácido metanosulfónico o el ácido clorhídrico en agua y a continuación se ajusta el pH en el intervalo [3, 5; 5].
CO97067661A 1996-11-19 1997-11-19 Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion CO4910113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614062A FR2755857B1 (fr) 1996-11-19 1996-11-19 Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation

Publications (1)

Publication Number Publication Date
CO4910113A1 true CO4910113A1 (es) 2000-04-24

Family

ID=9497744

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97067661A CO4910113A1 (es) 1996-11-19 1997-11-19 Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion

Country Status (45)

Country Link
US (1) US5994338A (es)
EP (1) EP0949923B1 (es)
JP (1) JP4278115B2 (es)
KR (1) KR100530836B1 (es)
CN (1) CN1146417C (es)
AP (1) AP998A (es)
AR (1) AR008695A1 (es)
AT (1) ATE223217T1 (es)
AU (1) AU740291B2 (es)
BG (1) BG63621B1 (es)
BR (1) BR9713087A (es)
CA (1) CA2271095C (es)
CO (1) CO4910113A1 (es)
CZ (1) CZ299913B6 (es)
DE (1) DE69715247T2 (es)
DK (1) DK0949923T3 (es)
DZ (1) DZ2349A1 (es)
EA (1) EA002025B1 (es)
EE (1) EE03668B1 (es)
ES (1) ES2179375T3 (es)
FR (1) FR2755857B1 (es)
HK (1) HK1022832A1 (es)
HR (1) HRP970615B1 (es)
HU (1) HUP9904327A3 (es)
IL (2) IL129607A0 (es)
IN (1) IN187038B (es)
JO (1) JO1992B1 (es)
MA (1) MA26448A1 (es)
MY (1) MY123805A (es)
NO (1) NO992399D0 (es)
NZ (1) NZ334949A (es)
OA (1) OA11047A (es)
PE (1) PE13999A1 (es)
PL (1) PL190164B1 (es)
PT (1) PT949923E (es)
RS (1) RS49608B (es)
SA (1) SA97180645B1 (es)
SK (1) SK284311B6 (es)
TN (1) TNSN97184A1 (es)
TR (1) TR199901096T2 (es)
TW (1) TW474816B (es)
UA (1) UA59376C2 (es)
UY (1) UY24780A1 (es)
WO (1) WO1998022107A1 (es)
ZA (1) ZA9710435B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
ATE322280T1 (de) 1998-09-25 2006-04-15 Cubist Pharm Inc Verwendung von daptomycin
ATE294571T1 (de) * 1999-03-03 2005-05-15 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
US6119269A (en) * 1999-09-23 2000-09-19 Imler; Jack Fishing vest with removable storage container system
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
FR2812549B1 (fr) * 2000-08-03 2003-03-21 Aventis Pharma Sa Associations dalfopristine/quinupristine avec le cefpirome
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549065B1 (fr) * 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2576022B1 (fr) * 1985-01-11 1987-09-11 Rhone Poulenc Sante Nouveaux derives de la pristinamycine ii b, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2599036B1 (fr) * 1986-05-22 1988-09-09 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
IL129607A0 (en) 2000-02-29
EP0949923B1 (fr) 2002-09-04
PE13999A1 (es) 1999-05-05
UY24780A1 (es) 2001-08-27
WO1998022107A1 (fr) 1998-05-28
NO992399L (no) 1999-05-19
SK284311B6 (sk) 2005-01-03
CZ299913B6 (cs) 2008-12-29
US5994338A (en) 1999-11-30
CN1233959A (zh) 1999-11-03
HRP970615A2 (en) 1998-08-31
HK1022832A1 (en) 2000-08-25
DZ2349A1 (fr) 2002-12-28
DE69715247D1 (de) 2002-10-10
PT949923E (pt) 2003-01-31
JP4278115B2 (ja) 2009-06-10
FR2755857B1 (fr) 1998-12-24
EP0949923A1 (fr) 1999-10-20
FR2755857A1 (fr) 1998-05-22
NO992399D0 (no) 1999-05-19
RS49608B (sr) 2007-06-04
ES2179375T3 (es) 2003-01-16
HRP970615B1 (en) 2002-12-31
CZ174899A3 (cs) 1999-08-11
AP998A (en) 2001-08-09
CA2271095C (fr) 2004-08-03
SK66099A3 (en) 2000-01-18
EE03668B1 (et) 2002-04-15
KR100530836B1 (ko) 2005-11-23
IL129607A (en) 2006-08-20
SA97180645B1 (ar) 2005-12-12
UA59376C2 (uk) 2003-09-15
TW474816B (en) 2002-02-01
EA002025B1 (ru) 2001-12-24
YU22499A (sh) 2002-03-18
TNSN97184A1 (fr) 2005-03-15
AU5125698A (en) 1998-06-10
NZ334949A (en) 2000-12-22
AU740291B2 (en) 2001-11-01
PL190164B1 (pl) 2005-11-30
EE9900127A (et) 1999-12-15
EA199900479A1 (ru) 2000-02-28
HUP9904327A2 (hu) 2000-06-28
HUP9904327A3 (en) 2002-03-28
ZA9710435B (en) 1998-06-10
MY123805A (en) 2006-06-30
CN1146417C (zh) 2004-04-21
OA11047A (fr) 2003-03-07
AR008695A1 (es) 2000-02-09
IN187038B (es) 2001-12-29
ATE223217T1 (de) 2002-09-15
BG103412A (en) 2000-06-30
BG63621B1 (bg) 2002-07-31
DK0949923T3 (da) 2002-12-23
BR9713087A (pt) 2000-03-28
KR20000053343A (ko) 2000-08-25
JO1992B1 (en) 1999-05-15
MA26448A1 (fr) 2004-12-20
TR199901096T2 (xx) 1999-07-21
JP2001504475A (ja) 2001-04-03
DE69715247T2 (de) 2003-04-30
CA2271095A1 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
NO965012L (no) Farmasöytisk preparat som omfatter glukagon
BR0008015A (pt) Uso de um composto, composto, composições farmacêuticas, e, processo para preparar um composto
AU5249898A (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
ATE202337T1 (de) Cyclopropylalkansäurederivate
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
DE3679128D1 (de) Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben.
HK1030604A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
DE69802113T2 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
HUP0002106A2 (hu) Transz-5-klór-2,3,3a,12b-tetrahidro-2-metil-1H-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol aromás szulfonátjai és az ezt tartalmazó gyógyszerkészítmények
CO4910113A1 (es) Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion
DE69631542D1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
ATE203665T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
AP9801235A0 (en) Erythromycin derivatives.
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse
RU93052408A (ru) Ациламино-алкилиден-гидрокси-бис-фосфоновые кислоты, способ их получения, фармацевтическая композиция
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
BG104162A (en) Pharmaceutical composition active in the reduction of the mcp-1 protein production
RU93057886A (ru) Производные 2-тиенилимидазо (2,1-b) бензтиазол-3-уксусной кислоты, способ их получения и фармацевтическая композиция на их основе
HUP9903183A2 (hu) Olanzapin alkalmazása fájdalomcsillapító hatású gyógyszerkészítmények előállítására
ITMI931174A0 (it) Composizioni farmaceutiche per la cura della talassemia
UY24851A1 (es) Derivados de ácidos n-acil-alfa-aminados
SI0841904T1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors